CellType
Product & Competitive Intelligence
Simulates human biology with AI to predict drug effects and run virtual trials.
Company Overview
Builds an agentic drug discovery platform that simulates human biology using foundation models (Cell2Sentence) and autonomous AI agents to predict drug effects, identify targets, and run virtual clinical trials, replacing traditional preclinical models.
Competitive Advantage & Moat
Product Roadmap & Public Announcements
CellType has open-sourced celltype-cli (MIT license) powered by Claude for autonomous drug discovery workflows. The platform integrates with 30+ biomedical APIs (PubMed, ChEMBL, UniProt). Cell2Sentence was presented at ICML 2024, and the scaled-up C2S-Scale 27B model was developed in collaboration with Google Research and Google DeepMind. Google CEO Sundar Pichai highlighted that the C2S-Scale 27B model generated a "novel hypothesis about cancer cellular behavior" that was subsequently validated experimentally. Enterprise on-premise deployment and GPU-accelerated models (CellType Agent Pro) are now available. All deals reported as inbound from top 10 pharma.
Signals & Private Analysis
Rapid iteration on multi-dataset integration and expansion to new therapeutic areas beyond oncology are likely underway. The "all deals are inbound from top 10 pharma" claim hints at undisclosed pilot agreements. Land-and-expand strategy: give away the research agent (open-source CLI), monetize the virtual human simulation engine. Likely Series A fundraise given pharma traction and Google DeepMind collaboration. GPU cloud offering (Agent Pro) suggests a path to recurring compute-based revenue.
Product Roadmap Priorities
Simulates drug effects across human cell types and tissues in silico to predict efficacy and toxicity before any wet-lab experiment.
Instead of testing drugs on mice and hoping they work in humans, CellType builds a digital twin of human biology and tests drugs on that first.
It's like crash-testing a car in a hyper-realistic video game before ever bending real metal—except the car is a drug and the game is a perfect simulation of your body.
Deploys autonomous AI agents that identify and validate novel drug targets by reasoning across multi-omics data and biomedical literature.
CellType's AI agents act like tireless PhD researchers that read every paper, analyze every dataset, and propose the best drug targets—all before your morning coffee.
It's like having a research assistant who has memorized every biology paper ever written, can run every analysis tool simultaneously, and never needs sleep—except it actually exists and works before lunch.
Uses foundation models to stratify virtual patient populations and predict clinical trial outcomes, enabling optimized trial design before recruiting a single patient.
CellType figures out which patients a drug will actually work for before the trial even starts, so pharma companies stop wasting billions testing drugs on the wrong people.
It's like a dating app for drugs and patients—instead of hoping for a random match, the AI figures out exactly who's compatible before anyone commits to a very expensive first date.
Company Overview
Key Team Members
- David van Dijk, Co-Founder & CEO
- Ivan Vrkic, Co-Founder
Founder Force Multiplier
David van Dijk is a Yale Assistant Professor of Medicine with 11,000+ citations and publications in Cell, Nature, ICML, and NeurIPS, who turned down Google to build CellType. Ivan Vrkic co-developed Cell2Sentence at Yale (published at ICML), built software to control CERN's Large Hadron Collider, and led large-scale foundation model training at a biotech company. Together they invented Cell2Sentence, uniquely enabling LLMs to natively reason about cellular biology as language, giving them first-mover advantage in applying transformer architectures to whole-system drug discovery.
Funding History
- 2024 | Cell2Sentence developed at Yale, presented at ICML 2024.
- 2025 | CellType founded; celltype-cli open-sourced (MIT license).
- 2025 | C2S-Scale 27B developed in collaboration with Google Research and Google DeepMind.
- 2026 | Accepted into Y Combinator Winter 2026 batch (~$500K).
- 2026 | Inbound partnerships from top 10 pharma companies.
Competitors
- Protein-Centric AI: Isomorphic Labs, Recursion, Insilico Medicine
- Foundation Model Bio: Genentech (scGPT), Microsoft (BioGPT), Owkin
- Virtual Biology: Cellarity, Relation Therapeutics
- Agentic Drug Discovery: FutureHouse (Robin), Emerald Cloud Lab
